Resumen de: CN120381441A
本发明公开了一种用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子及其制备方法与应用,属于生物医药技术领域。本发明的纳米粒子以铁蛋白为载体,其内包裹有能够上调线粒体铁转运蛋白的siRNA,表面修饰有E3连接酶配体和肿瘤靶向肽,其制备方法包括:通过Click反应将E3连接酶配体和肿瘤靶向肽修饰在铁蛋白表面;利用铁蛋白的pH依赖性解聚/重组特性,将siRNA装载到铁蛋白载体中,获得用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子。本发明的纳米粒子能有效躲避肝脏的清除,有效富集在肿瘤部位,通过破坏肿瘤细胞线粒体内铁稳态,诱导肿瘤细胞死亡,进而激活强大的抗肿瘤免疫,其可用于制备抗肿瘤药物。
Resumen de: CN120381429A
本发明公开了一种可溶性纳米微针及其制备方法和应用,涉及纳米微针领域。本发明在制备可溶性纳米微针时,将吡咯、苯甲醛、对羟基苯甲醛、1,6‑二溴己烷反应制得季铵化卟啉;将聚乳酸‑羟基乙酸共聚物、季铵化卟啉通过乳液法制得载药纳米微球;再将聚乙烯醇溶液、载药纳米微球通过模板法制得。本发明制备的可溶性纳米微针具有良好的药物释放效果,药物利用率高,且刺激性低。
Resumen de: CN120381531A
本发明涉及载药粒子技术领域,尤其涉及一种载药纳米粒子及金属多酚网络介导的可食源性组装体,将天然硫化物包覆在含有介孔结构的碳酸钙中形成所述载药纳米粒子,并将载药纳米粒子的外层包裹上具有金属‑多酚网络结构的纳米涂层,得到金属多酚网络介导的可食源性组装体,用于制备治疗酒精损伤的药物,所述药物有助于减轻酒精造成的组织损伤和行为障碍。
Resumen de: CN120381440A
本发明公开了具有pH响应性和肿瘤靶向性的siRNA递送载体CCM‑CS/ZnO@siSurvivin,公开了其制备方法,公开了其形态、结构等理化性质,公开了其包封率、释药行为,公开了其细胞摄取效率、肿瘤靶向能力、溶酶体逃逸能力、基因沉默效率、促凋亡能力、肿瘤细胞生长抑制能力,公开了Survivin siRNA和ZnO协同抗肿瘤能力,进一步公开了其体内靶向性以及抑制BALB/c荷瘤裸鼠肿瘤生长的作用和体内安全性。进而阐明了该靶向递送载体在肿瘤的基因治疗领域具有重要的应用。
Resumen de: CN120383729A
本发明涉及生物医药技术领域,尤其涉及一种用于器官选择性递送核酸药物的类脂质分子、类脂质纳米颗粒及其应用、类脂质纳米颗粒‑核酸复合物及其制备方法。本发明提供的类脂质分子是由聚乙烯亚胺与芳基丙烯酸酯发生迈克尔加成反应得到,合成方法简单安全,反应条件温和,成本低;所述类脂质纳米颗粒按质量百分比计由如下组分组成:类脂质分子30~80%,甾醇5~50%,聚乙二醇‑脂质5~40%,辅助脂质5~50%。本发明的优点在于通过调节类脂质分子自身的化学结构实现了其类脂质纳米颗粒在受试生物体内对核酸药物的器官选择性递送。
Resumen de: CN120383680A
本发明公开了一种高效降解目标蛋白的PROTAC及其制备和递送方法,将相分离序列与设计的双靶向分子融合,分别靶向目标蛋白以及蛋白酶体,实现PROTAC与目标蛋白的相分离,从而实现目标蛋白的高效降解。通过LNP包封mRNA也实现了PROTAC的递送,同样可以在细胞内高效降解目标蛋白,这也为肽类或蛋白类PROTAC向人体内的递送提供了一种途径。
Resumen de: WO2024112882A1
The present invention relates to compositions for effective delivery of gene editing agents to a target cell, as well as methods of use thereof for the treatment of a disease or disorder.
Resumen de: MX2025006877A
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: WO2024098127A1
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous solubility, is encapsulated in a nanostructured lipid system comprising a solid lipid, a liquid lipid, a surfactant and a co-surfactant. Optionally, the system of the invention can be additionally coated with an antibacterial cationic agent. The nanostructured lipid system according to the invention allows the topical administration of besifloxacin in the eyes and gives the drug a longer retention time on the surface of the eye. Furthermore, the system described herein is designed using industrially applicable methods and remains stable under storage conditions for at least 90 days, so it can be readily reproduced on an industrial scale.
Resumen de: CN120361244A
本发明公开了一种电诱导辅助制备的营养递送体系及其制备方法和应用,制备方法为:将两亲性成壳蛋白和脂溶性的包埋物分别溶于溶剂A中,得到包埋物/两亲性成壳蛋白溶液,将其滴加到溶剂B或壳聚糖的C溶液中,所述壳聚糖溶液由壳聚糖溶解到溶剂C中得到,在滴加过程中通入40V,100mA的持续电流,包埋物/两亲性成壳蛋白在溶剂A或溶剂C中析出,负压蒸发,调节pH值,得到电诱导辅助制备的载包埋物的两亲性成壳蛋白基纳米颗粒或两亲性成壳蛋白基‑壳聚糖纳米颗粒,两者均为核壳结构,包埋物为核,两亲性成壳蛋白或被壳聚糖修饰的两亲性成壳蛋白为壳。本发明采用电诱导法辅助制备营养递送体系具有简便高效,反应条件温和,无毒副作用等特点。
Resumen de: US2025230471A1
The present disclosure provides compositions and methods for inserting heterologous payload sequences into a target-site in a host cell genome. The compositions and methods use non-LTR retrotransposon reverse transcriptase proteins that bind template RNAs comprising a payload sequence that encodes a protein or regulatory RNA. The template RNA can comprise modified uridines that are not cleavable by a ribozyme. The incorporation of modified uridines increases the efficiency of integration and expression of the payload sequence and decreases cellular toxicity.
Resumen de: CN120361008A
本发明提供了基于米尔贝肟吡喹酮的寄生虫驱除药物,以质量份计,所述药物包括以下组分:改性米尔贝肟10‑30份、纳米包覆吡喹酮20‑50份、复配增效剂5‑15份、矫味剂3‑8份、崩解剂2‑5份。基于米尔贝肟吡喹酮的寄生虫驱除药物的应用,所述药物用于制备预防或治疗犬、猫的混合寄生虫感染的制剂,所述寄生虫包括绦虫、线虫、吸虫及蠕形螨。本申请通过化学改性(琥珀酰化米尔贝肟)、纳米技术(HPMC包覆吡喹酮)、复配协同(非班太尔‑β环糊精)的集成创新,实现广谱驱虫、长效稳定、安全低毒的综合优势,同时解决现有技术中适口性差、代谢负担高、环境适应性弱等痛点,适用于犬猫混合寄生虫感染的预防与治疗。
Resumen de: CN120364654A
本申请提供了一种红色纳米硒颗粒的制备方法及其应用,涉及纳米医药技术领域,制备方法包括将亚硒酸钠溶于超纯水,加入含铜锌铝硅酸盐微球,pH至4.8,搅拌滴加1.5M抗坏血酸溶液,升温至加入固体抗坏血酸,用NaOH调节pH,搅拌反应得到纳米硒悬浮液;将纳米硒悬浮液、海藻酸钠巯基氧化石墨烯混合物和壳寡糖柠檬酸缓冲液混合搅拌,离心洗涤后冷冻干燥,得到红色纳米硒颗粒,所述含铜锌铝硅酸盐微球通过介孔模板煅烧及铜锌共掺杂制备,用该方法制备出的红色纳米硒颗粒具有核壳结构,粒径均一且抗氧化性强的同时具有显著的界面结合强度。
Resumen de: US2024245618A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: WO2024177578A1
A method of producing a biomolecule-crosslinked compound is disclosed. More specifically, the method comprises the steps of reacting a plurality of monomers and a plurality of comonomers in the presence of ammonia within a first solution to generate a compound; retrieving the produced compound from the first solution for cleaning; subjecting the cleaned compound to react with a second solution to join a crosslinker onto the compound through a first amine functional group of the crosslinker; and adding a plurality of biomolecules to the second solution to bind the biomolecules towards the compound through a second amine functional group of the crosslinker to produce the biomolecule-crosslinked compound.
Resumen de: CN120361109A
本发明涉及一种去腐生肌抗感染药膏及其制备方法,属于中药技术领域。本发明以地榆、黄连、黄柏、黄芩、虎杖、紫草、冰片、蜂蜡、香油为基础原料制备去腐生肌抗感染药膏;将地榆提取物制成pH响应纳米粒和紫草提取物制成紫草提取物‑硫辛酸复合物靶向坏死组织释放活性物质,促进坏死组织的自然去除,同时保护健康组织。
Resumen de: AU2023408183A1
Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a histidine buffer. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.
Resumen de: WO2025153097A1
The use of blank lipid nanoparticles in the preparation of an in-vivo delivery product, comprising the step of mixing the blank lipid nanoparticles with a biologically active substance in a solvent to obtain a blank lipid nanoparticle-based composition. The blank lipid nanoparticles consist of an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-lipid conjugate. According to the blank lipid nanoparticles, the dosage of the biologically active substance can be flexibly adjusted according to the requirements of a user, and the blank lipid nanoparticles can be administered via multiple routes such as intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, all of which can achieve an ideal delivery effect.
Resumen de: CN120360968A
本申请提供一种麦角甾醇纳米分散体及其制备方法和应用,麦角甾醇纳米分散体包括麦角甾醇芯材和包裹所述麦角甾醇芯材至少部分表面的大豆分离蛋白壁材,所述分散体的粒径为250‑400 nm,所述分散体的PDI为0.034‑0.106。该分散体特殊的组成及相关参数,显著改善了麦角甾醇在水中的分散性、均一性和生物可及性。
Resumen de: CN120361241A
本发明涉及一种白蛋白功能化硫化钽纳米点在制备治疗急性肾损伤药物中的应用,属于纳米药物新用途技术领域。本发明所用的白蛋白功能化硫化钽纳米点由安全无毒且无免疫原性的理想载体白蛋白和高生物相容的层状过渡金属硫化钽简单高效组装而成;能够凭借其超小粒径穿越肾小球滤过屏障特异性蓄积于肾脏,利用白蛋白与巨蛋白受体的特异性结合主动内化至近端小管上皮细胞,又依赖白蛋白对线粒体的高亲和力序贯定位至线粒体。该纳米点在急性肾损伤病理损伤微环境中通过钽离子活跃的价态变化高效清除活性氧并保护线粒体,限制细胞凋亡、免疫激活及无菌性炎症,进而实现近端小管上皮细胞损伤缓解并有效恢复肾脏功能。
Resumen de: CN120360969A
本发明公开了双靶向巨噬细胞膜纳米系统及其制备方法与应用,属于生物医药领域,MKA由AuNPs与线粒体靶向肽KLA连接后包裹于巨噬细胞膜内。制备时先合成AuNPs并修饰,再用巨噬细胞膜包裹。在治疗中,它能双靶向肿瘤细胞和线粒体,增强辐射诱导的DNA损伤,抑制DDR,激活免疫通路,促进T细胞浸润,还可消耗谷胱甘肽、放大氧化应激来增强免疫效果,与8GyX射线协同的剂量增强比达3.1。此外,MKA在体内生物相容性良好,血液循环时间长、肿瘤靶向性高且能快速经肾脏清除。该发明为肿瘤放射免疫治疗提供新途径,有助于推动临床肿瘤治疗的进步。
Resumen de: CN120360965A
本发明公开了一种基于多酚氧化偶联自组装的pH响应性口服纳米药物及其制备方法和应用。该纳米药物设计简单高效,本发明所述的纳米药物是基于多酚在酸性介质中通过氧化剂介导的氧化偶联自组装,提供了一种耐酸不耐碱的pH响应性口服递送载体。通过溶剂转换介导的解组装‑重组装作用,高效负载疏水性药物,制备得到口服纳米药物。本纳米策略极大的提高了疏水性药物的载药率,载药量高达50%。同时避免了纳米药物被恶劣的胃生理环境破坏,靶向肠道递送。基于生物活性的多酚载体与药物之间的双重抗炎抗氧化作用,该口服纳米药物能够作为优异的多功能药物制剂通过协同作用预防或治疗炎症性肠病。
Resumen de: CN120360189A
本发明公开了一种幼鹅养殖饲料,属于养殖饲料技术领域,来解决现有改进型饲料仍存在配方复杂、成本高、效果不稳定的问题,能量原料占55‑68%,优选62%;蛋白原料占22‑30%,优选26%;预混料占5‑8%,优选6.5%;功能添加剂占3‑7%,优选5.5%,通过复合酶制剂与微生态制剂的协同作用,显著提高了粗蛋白消化率,使其提升至78.6%(P<0.01),有效提高了饲料的利用效率,利用纳米包被技术形成的缓释体系,使维生素D3半衰期延长至48小时,持续为幼鹅提供稳定的维生素D3来源,促进钙、磷吸收和骨骼发育,根据幼鹅不同生长阶段对钙、磷的需求,将钙磷比在1.8:1‑2.2:1进行梯度调整,满足幼鹅骨骼发育和新陈代谢的需求,减少因钙磷失衡导致的疾病。
Resumen de: CN120361235A
本发明提供了一种双靶向类载体材料、制备方法、及其包裹的齐墩果酸纳米粒的制备方法,属于医药技术领域。以双靶向性的高分子共聚物为载体材料,采用乳化‑溶剂挥发法制备齐墩果酸靶向纳米粒,能够保护齐墩果酸不被快速降解,延长其在体内的循环时间。同时,通过靶向基团,实现对齐墩果酸的靶向递送,提高药物在肿瘤组织的浓度,降低对正常组织的毒副作用。采用MTT法,研究齐墩果酸纳米粒对细胞生长的抑制作用,结果显示,齐墩果酸靶向纳米粒具有相对于齐墩果酸原料药具有更强的抑制肿瘤细胞增殖的作用。
Nº publicación: US2025235524A1 24/07/2025
Solicitante:
PFIZER INC [US]
Pfizer Inc
Resumen de: US2025235524A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.